ImmuPharma plc (LON:IMM – Get Free Report)’s stock price was up 23.8% during mid-day trading on Saturday . The stock traded as high as GBX 5.70 ($0.07) and last traded at GBX 4.83 ($0.06). 16,731,404 shares were traded during trading, a decline of 23% from the average daily volume of 21,725,510 shares. The stock had previously closed at GBX 3.90 ($0.05).
ImmuPharma Stock Performance
The company has a market capitalization of £20.11 million, a P/E ratio of -483.00 and a beta of 1.53. The business’s fifty day simple moving average is GBX 2.46 and its 200-day simple moving average is GBX 1.95.
About ImmuPharma
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
See Also
- Five stocks we like better than ImmuPharma
- Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
- Why New Tariffs Could Boost These 3 Basic Materials Stocks
- How to invest in marijuana stocks in 7 steps
- MarketBeat Week in Review – 02/03 – 02/07
- Stock Market Upgrades: What Are They?
- Meta Platforms Continues to Prove Why It’s a Premier Play on AI
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
